Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL28486089 | 0.86 | ALOX5 (0.47) | ALOX5TSHRPIK3CDGAAKMT2A | |
| SCHEMBL6012088 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL430004 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL297738 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL297935 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL705126 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL707139 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL37427 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL7895656 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A | |
| SCHEMBL6575811 | 0.85 | ALOX5 (0.53) | ALOX5PIK3CDGAAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | CYP1A2 2743/4885ALOX5 1389/4885MALT1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.